Condition: Small-cell Lung Cancer · Residual Tumor · Radiation · Sponsor: Qingdao Central Hospital
This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors, treatment resistance inevitably happens. Residual tumor irradiation my prolong drug resistance, and may help prevent the growth and spread of the tumor cells to other parts of the body.
This description comes directly from the study's public registry record.
chunling zhang, md · 1718865657 · kevinji78@yahoo.com
Always discuss trial participation with your own doctor first.
| Qingdao Central Hospital | Qingdao, Shandong, China | Recruiting |
| Qingdao Central Hospital | Qingdao, Shandong, China | Recruiting |
| Qingdao Central Hospital | Qingdao, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06514118